Literature DB >> 18936777

Cancer exploiting complement: a clue or an exception?

Bruce E Loveland, Jonathan Cebon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18936777     DOI: 10.1038/ni1108-1205

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  14 in total

Review 1.  Is complement good or bad for cancer patients? A new perspective on an old dilemma.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Trends Immunol       Date:  2009-05-08       Impact factor: 16.687

2.  Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake.

Authors:  Swetha Inturi; Guankui Wang; Fangfang Chen; Nirmal K Banda; V Michael Holers; LinPing Wu; Seyed Moein Moghimi; Dmitri Simberg
Journal:  ACS Nano       Date:  2015-10-21       Impact factor: 15.881

3.  Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

Authors:  A Michlmayr; T Bachleitner-Hofmann; S Baumann; M Marchetti-Deschmann; I Rech-Weichselbraun; C Burghuber; U Pluschnig; R Bartsch; A Graf; R Greil; G Allmaier; G Steger; M Gnant; M Bergmann; R Oehler
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

Review 4.  Unwelcome complement.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 5.  Complement anaphylatoxins as immune regulators in cancer.

Authors:  Eli T Sayegh; Orin Bloch; Andrew T Parsa
Journal:  Cancer Med       Date:  2014-04-08       Impact factor: 4.452

6.  Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.

Authors:  Andrea Facciabene; Francesco De Sanctis; Stefano Pierini; Edimara S Reis; Klara Balint; John Facciponte; Jens Rueter; Masahiro Kagabu; Paola Magotti; Evripidis Lanitis; Robert A DeAngelis; Ronald J Buckanovich; Wenchao C Song; John D Lambris; George Coukos
Journal:  Oncoimmunology       Date:  2017-06-08       Impact factor: 8.110

Review 7.  Complementing Cancer Metastasis.

Authors:  Dawn M Kochanek; Shanawaz M Ghouse; Magdalena M Karbowniczek; Maciej M Markiewski
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

8.  Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics.

Authors:  Hamad Alshetaiwi; Nicholas Pervolarakis; Laura Lynn McIntyre; Dennis Ma; Quy Nguyen; Jan Akara Rath; Kevin Nee; Grace Hernandez; Katrina Evans; Leona Torosian; Anushka Silva; Craig Walsh; Kai Kessenbrock
Journal:  Sci Immunol       Date:  2020-02-21

9.  C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.

Authors:  Roberta Bulla; Claudio Tripodo; Damiano Rami; Guang Sheng Ling; Chiara Agostinis; Carla Guarnotta; Sonia Zorzet; Paolo Durigutto; Marina Botto; Francesco Tedesco
Journal:  Nat Commun       Date:  2016-02-01       Impact factor: 14.919

10.  Extracellular vesicles from KSHV-infected endothelial cells activate the complement system.

Authors:  Hyungtaek Jeon; Seung-Min Yoo; Hyo Sun Choi; Ji Young Mun; Hee-Gyoo Kang; Jiyeong Lee; Jinsung Park; Shou-Jiang Gao; Myung-Shin Lee
Journal:  Oncotarget       Date:  2017-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.